A systematic review and meta-analysis of clinical trials comparing arterolane-piperaquine vs. artemether-lumefantrine for the treatment of uncomplicated falciparum malaria
Authors:
Open Access
- 1 October 2025
- journal article
- review article
- Published by Wolters Kluwer Health in Journal of Postgraduate Medicine
- Vol. 71 (4) , 170-179
Abstract
Introduction: Artemisinin combination therapy (ACT) is the World Health Organization (WHO) recommended first-line therapy for falciparum malaria. However, recent concern is ACT resistance. Arterolane-piperaquine is a synthetic alternative to ACT. Our objective was to determine the safety and efficacy of arterolane-piperaquine in comparison with artemether-lumefantrine for the treatment of falciparum malaria. Material and Methods: We conducted a systematic review and meta-analysis to determine the safety and efficacy of arterolane maleate and piperaquine phosphate for the treatment of uncomplicated falciparum malaria. We searched PubMed/MEDLINE, Cochrane Library, Google Scholar, Clinical Trials.gov and MedRxiv. Search results were screened by title, abstract, and full text before inclusion into the study. Meta-analysis of risk difference between arterolane-piperaquine and artemether-lumefantrine in regard to safety and efficacy was done using a random effects model. Results: Four randomized controlled trials (RCTs) were included. One RCT had a high risk of bias, while the other three studies had a low risk of bias. The 28-day polymerase chain reaction (PCR) corrected risk difference between the artemether-lumefantrine and arterolane-piperaquine was 0 (95% confidence interval −0.02 to 0.02), whereas the PCR uncorrected risk difference was 0.11 (95% confidence interval −0.06 to 0.27). On 42-day follow-up, the PCR uncorrected risk difference was 0.17 (95% confidence interval −0.05 to 0.38), while the PCR-corrected risk difference was 0.01 (95% confidence interval −0.01 to 0.03). Adverse effect profile was similar with risk difference of at least one adverse effect being −0.01 (95% confidence interval −0.02 to 0.00). The commonly reported adverse effects of arterolane-piperaquine were vomiting, anemia, and pain abdomen. Conclusions: Our study shows that arterolane-piperaquine is non-inferior to artemether-lumefantrine for the treatment of uncomplicated falciparum malaria.Keywords
This publication has 10 references indexed in Scilit:
- Mapping genetic markers of artemisinin resistance in Plasmodium falciparum malaria in Asia: a systematic review and spatiotemporal analysisThe Lancet Microbe, 2022
- Arterolane–piperaquine–mefloquine versus arterolane–piperaquine and artemether–lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children: a single-centre, open-label, randomised, non-inferiority trialThe Lancet Infectious Diseases, 2021
- Evidence of Artemisinin-Resistant Malaria in AfricaNew England Journal of Medicine, 2021
- Artemisinin inspired synthetic endoperoxide drug candidates: Design, synthesis, and mechanism of action studiesMedicinal Research Reviews, 2021
- The PRISMA 2020 statement: an updated guideline for reporting systematic reviewsBMJ, 2021
- Risk‐of‐bias VISualization (robvis): An R package and Shiny web app for visualizing risk‐of‐bias assessmentsResearch Synthesis Methods, 2020
- RoB 2: a revised tool for assessing risk of bias in randomised trialsBMJ, 2019
- Assessment of Efficacy and Safety of Arterolane Maleate–Piperaquine Phosphate Dispersible Tablets in Comparison With Artemether-Lumefantrine Dispersible Tablets in Pediatric Patients With Acute Uncomplicated Plasmodium falciparum Malaria: A Phase 3, Randomized, Multicenter Trial in India and AfricaClinical Infectious Diseases, 2017
- A Phase 3, Double-Blind, Randomized Study of Arterolane Maleate–Piperaquine Phosphate vs Artemether–Lumefantrine for Falciparum Malaria in Adolescent and Adult Patients in Asia and AfricaClinical Infectious Diseases, 2016
- Arterolane Maleate Plus Piperaquine Phosphate for Treatment of Uncomplicated Plasmodium falciparum Malaria: A Comparative, Multicenter, Randomized Clinical TrialClinical Infectious Diseases, 2012